^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CAR19-CYNK
i
Other names: CAR19-CYNK
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Celularity
Drug class:
CD19 inhibitor, NK cell stimulant
Related drugs:
3years
Development of CD19 CAR Engineered Human Placental CD34+-Derived Natural Killer Cells (CAR19-CYNK) As an Allogeneic Cancer Immunotherapy (ASH 2021)
Luciferase expressing Daudi cells (3×10 6 ) were intravenously (IV) injected on Day 0 three days after the mice were preconditioned with a myeloablative dose of busulfan to allow for better tumor cell engraftment... In summary, we have successfully established a process for generating CAR19-CYNK cells from human placental CD34 + cells. CAR19-CYNK demonstrated enhanced in vitro cytotoxicity against CD19 + B cell malignancies and in vivo survival benefit in a disseminated lymphoma xenograft B-NDG-hIL15 model. Further development of CAR19-CYNK for CD19 + B cell malignancies is warranted.
IO biomarker
|
CD19 (CD19 Molecule) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD34 (CD34 molecule) • NCAM1 (Neural cell adhesion molecule 1) • CSF2 (Colony stimulating factor 2) • NKG2D (killer cell lectin like receptor K1)
|
CD19 expression
|
busulfan • CAR19-CYNK • ROR1.TNK
Share via
